• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMU 8.97% 7.1¢

IMUGENE LIMITED - Corporate Spotlight

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

No Corporate Spotlight currently available.

(20min delay)
Last
7.1¢
Change
-0.007(8.97%)
Mkt cap ! $519.7M
Open High Low Value Volume
7.8¢ 8.0¢ 7.0¢ $4.930M 66.98M

Buyers (Bids)

No. Vol. Price($)
3 571382 7.1¢
 

Sellers (Offers)

Price($) Vol. No.
7.2¢ 1102836 5
View Market Depth
Last trade - 16.10pm 19/04/2024 (20 minute delay) ?
Last
7.1¢
  Change
-0.007 ( 10.7 %)
Open High Low Volume
7.8¢ 8.0¢ 7.0¢ 28787854
Last updated 15.59pm 19/04/2024 ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.